Amgen Inc. (NASDAQ:AMGN) Shares Purchased by Apeiron RIA LLC

Apeiron RIA LLC increased its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 21.9% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 2,744 shares of the medical research company’s stock after acquiring an additional 493 shares during the quarter. Apeiron RIA LLC’s holdings in Amgen were worth $715,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. Capital Performance Advisors LLP purchased a new stake in shares of Amgen in the third quarter valued at about $25,000. Legacy Investment Solutions LLC acquired a new position in Amgen in the 3rd quarter valued at about $29,000. Hershey Financial Advisers LLC purchased a new stake in shares of Amgen in the 2nd quarter valued at approximately $30,000. Matrix Trust Co acquired a new stake in shares of Amgen during the 3rd quarter worth approximately $36,000. Finally, Livelsberger Financial Advisory purchased a new stake in shares of Amgen during the 3rd quarter valued at approximately $56,000. 76.50% of the stock is currently owned by hedge funds and other institutional investors.

Amgen Stock Performance

Shares of AMGN stock opened at $277.88 on Friday. The company has a market cap of $149.37 billion, a P/E ratio of 35.58, a PEG ratio of 2.79 and a beta of 0.56. The firm has a fifty day moving average price of $271.91 and a 200 day moving average price of $306.43. The company has a current ratio of 1.32, a quick ratio of 0.96 and a debt-to-equity ratio of 7.55. Amgen Inc. has a 12 month low of $253.30 and a 12 month high of $346.85.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Wednesday, October 30th. The medical research company reported $5.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.11 by $0.47. Amgen had a return on equity of 168.35% and a net margin of 13.00%. The business had revenue of $8.50 billion during the quarter, compared to analysts’ expectations of $8.50 billion. During the same period in the prior year, the firm posted $4.96 EPS. The business’s quarterly revenue was up 23.2% compared to the same quarter last year. Sell-side analysts predict that Amgen Inc. will post 19.57 earnings per share for the current fiscal year.

Amgen Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, February 14th will be given a dividend of $2.38 per share. This represents a $9.52 annualized dividend and a dividend yield of 3.43%. The ex-dividend date is Friday, February 14th. This is an increase from Amgen’s previous quarterly dividend of $2.25. Amgen’s payout ratio is currently 115.24%.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on AMGN shares. Wells Fargo & Company cut their target price on Amgen from $335.00 to $280.00 and set an “equal weight” rating for the company in a research note on Friday, January 10th. Wolfe Research began coverage on shares of Amgen in a report on Friday, November 15th. They issued a “peer perform” rating on the stock. Sanford C. Bernstein assumed coverage on shares of Amgen in a research note on Thursday, October 17th. They set an “outperform” rating and a $380.00 target price for the company. Redburn Partners reduced their price target on shares of Amgen from $200.00 to $195.00 in a research note on Wednesday, November 27th. Finally, Truist Financial lowered their price objective on shares of Amgen from $333.00 to $298.00 and set a “hold” rating for the company in a research report on Wednesday, January 8th. Two research analysts have rated the stock with a sell rating, twelve have issued a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $314.91.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.